PHASE 1/2A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | NYU Langone Health

Go Back to All Clinical Trials

PHASE 1/2A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Platinum Resistant Epithelial Ovarian Cancer
Advanced Or Metastatic Sclc
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:
1. Diagnosis of locally advanced/unresectable or metastatic (stage IV) breast cancer, Small Cell Lung Cancer and/or select gynecologic malignancies including ovarian cancer.
2. ECOG PS 0 or 1.

You may not be eligible for this study if the following are true:

1. Participants with known symptomatic brain metastases requiring steroids.
2. Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
3. Major surgery within 3 weeks prior to study entry and radiation therapy within 3 weeks prior to study entry.